Ladies Luncheon Returns to Austin Country Club on September 26 for an "Afternoon in NYC" Benefiting CureDuchenne

Annual Event Features an Afternoon of Fashion and Fun to Raise Funds to Help Find a Cure for Duchenne Muscular Dystrophy

AUSTIN, Texas (August 5, 2024) – CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced the return of the sixth annual Ladies Luncheon at the Austin Country Club on Thursday, September 26, 2024. The Ladies Luncheon, started by Austin residents Tim and Laura Revell and hosted by Venus Strawn and Jennifer Stevens, will once again bring some of the most influential women in Austin together to connect and raise funds for a cure for Duchenne muscular dystrophy. This year's event invites attendees to experience an "Afternoon in NYC," where they will be transported to the glamour of the Big Apple. Guests will sip cosmos while previewing the hottest fashion trends from stores in The Domain. The dazzling event, featuring exciting raffles, networking opportunities, and an elegant lunch, will be emceed by Holly Mills-Gardner.

Tim and Laura Revell learned their two sons Timothy and Andrew were diagnosed with Duchenne, one of the most common and severe forms of muscular dystrophy, at just two and five years old. At the time of their boys' diagnoses, treatments and information on Duchenne was limited. The Revells began to research the rare disease and connected with CureDuchenne for resources. Tim and Laura have created several annual fundraising events to raise awareness and funds for CureDuchenne, including marathons, galas and the annual Ladies Luncheon. To date, the family has helped raise more than $6.6 million through their collective fundraising efforts.

"The unwavering support from our beloved Austin community through events like the Ladies Luncheon mean the world to our family," said Laura Revell. "We are more inspired than ever to achieve our mission – find a cure for our two boys and the thousands of others that are diagnosed with Duchenne muscular dystrophy. We know that our efforts in support of CureDuchenne's tireless work are making an impact, and we are grateful for our community of families that support one another through this journey that we share."

Duchenne muscular dystrophy, one of the most common and severe forms of muscular dystrophy, is a genetic disease affecting roughly 1 in 5,000 male births. Individuals with Duchenne are typically diagnosed as toddlers, lose the ability to walk in their early teens, and often succumb to the disease in their late 20s. Since CureDuchenne was founded in 2003, the organization has invested more than $26M in research and has funded 18 research projects that have advanced to human clinical trials.

"We could not do what we do without the generous support from families like the Revells and the wonderful Austin community," said Debra Miller, founder and CEO of CureDuchenne. "We have seen significant scientific progress recently, and we must continue the momentum by funding critical research so that ALL individuals with Duchenne have access to a transformative treatment that works for them. Funds raised at the Ladies Luncheon continue to drive our mission forward, and we are closer than ever."

Tickets for the Ladies Luncheon are available for $200, and sponsorships are also available. Current sponsors include Trendsetter Table Host, Fashionista Table Host, Underwriting Opportunities, Entertainment Sponsorship, and Presenting Sponsorship. For sponsorship information, tickets, and event details, visit: https://cureduchenne.org/event/ladies-luncheon-austin/.

About CureDuchenne

Twenty years ago, CureDuchenne was created with one goal: to find and fund a cure for Duchenne muscular dystrophy, one of the most common and severe forms of muscular dystrophy. Today, CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne. CureDuchenne's innovative venture philanthropy model has advanced transformative treatments for Duchenne muscular dystrophy, including 18 projects that advanced to human clinical trials and multiple projects to overcome the limitations of exon-skipping and gene therapy. In addition, CureDuchenne contributed early funding to the first FDA-approved Duchenne drug, pioneered the first and only Duchenne physical and occupational therapist certification program and created an innovative biobank and data registry, accelerating research toward a cure. For more information on how to help raise awareness and funds needed for research, please visit cureduchenne.org.

###